Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
NCT ID: NCT00299507
Last Updated: 2012-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
240 participants
INTERVENTIONAL
2005-03-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
15 mg Anecortave Acetate, 3 month intervals
Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
Anecortave Acetate Sterile Suspension, 30 mg/mL
One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
15 mg Anecortave Acetate, 6 month intervals
Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
Anecortave Acetate Sterile Suspension, 30 mg/mL
One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
30 mg Anecortave Acetate, 6 month intervals
Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
Anecortave Acetate Sterile Suspension, 60 mg/mL
One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
Anecortave Acetate Vehicle
One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
Anecortave Acetate Vehicle
One 0.5 mL sham injection at 6 month intervals
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anecortave Acetate Sterile Suspension, 30 mg/mL
One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
Anecortave Acetate Sterile Suspension, 60 mg/mL
One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
Anecortave Acetate Vehicle
One 0.5 mL sham injection at 6 month intervals
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alcon Investigators
Role: PRINCIPAL_INVESTIGATOR
Alcon Research
Patricia Zilliox, Ph.D.
Role: STUDY_DIRECTOR
Alcon Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alcon Study Sites
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-04-59
Identifier Type: -
Identifier Source: org_study_id